CytoMed Therapeutics Advances CAR-T Trials with Major Grant
CytoMed Therapeutics Launches Innovative CAR-T Cell Therapy Trial
CytoMed Therapeutics Limited (NASDAQ: GDTC), a prominent biopharmaceutical company based in Singapore, has received the green light for its groundbreaking Phase I clinical trial, known as the ANGELICA Trial. This trial explores the efficacy of a patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) therapy aimed at treating both blood and solid tumors. With significant financial backing from the National Medical Research Council (NMRC) through the Clinical Trial Grant, CytoMed is set to transform the landscape of cancer treatment.
Understanding CAR-T Cell Therapy
CAR-T cell therapy has emerged as a dynamic approach to oncology. This personalized therapy modifies a patient's own T cells by attaching a synthetic protein to target cancer cells specifically. The modified cells are reintroduced into the patient's body where they seek out and destroy malignancies without harming healthy cells, differentiating them from traditional chemotherapy that indiscriminately targets all rapidly dividing cells.
Benefits of the ANGELICA Trial
The ANGELICA Trial utilizes blood derived from healthy young donors, which is expected to lead to a higher quality of manufactured CAR-T cells. This approach not only lowers production costs but also facilitates quicker patient access to treatment, thanks to its potential for bulk production.
Unique Immune Cell Application
One of the distinctive features of CytoMed's trial is the use of gamma delta T cells instead of the conventional alpha-beta T cells. Gamma delta T cells can be sourced from healthy donors and do not require matching, making them versatile for various patients combating advanced cancer.
Expert Insights on the Trial
Dr. Anand Jeyasekharan, who leads this pioneering trial, emphasizes its unique approach to allogeneic CAR-T cell therapy, particularly for solid tumors. His team of experts has meticulously crafted the trial protocol to maximize its effectiveness and safety, ensuring that patients with relapsed cancers have access to innovative treatment options.
Dr. Tan Wee Kiat, Co-CEO and COO of CytoMed, expressed optimism about the trial and its potential contributions to the advancement of blood-derived immunotherapy in Singapore and globally.
Two-Part Trial Approach
The ANGELICA Trial consists of two segments. Currently, Part 1 is focused on recruiting healthy blood donors at the National University Hospital (NUH). Following this, Part 2 will aim to recruit patients suffering from advanced cancers that are unresponsive to standard therapies. This systematic approach could represent a significant milestone in patient care.
Acquisition of Cord Blood Bank
In an exciting development, CytoMed has also acquired assets of a licensed cord blood bank in Malaysia, enhancing its portfolio in cell-based therapies. This acquisition opens up new avenues utilizing cord blood-derived biologics, which bear potential for regenerative medicine and treatment of aging-related conditions, thus augmenting CytoMed's innovative capabilities.
Future Conferences and Opportunities
On October 8, CytoMed will hold an earnings call discussing its recent financials. This meeting represents an opportunity for stakeholders to engage with the management team and inquire about the company's future directions and the ANGELICA Trial outcomes.
Engagement with Investors
The management team will also be in New York City for meetings with shareholders from late October, allowing investors keen on CytoMed's path forward to discuss matters in person.
About CytoMed Therapeutics Limited
Founded in 2018 as a spin-off from Singapore’s A*STAR, CytoMed is dedicated to advancing the field of cancer treatment through innovative biopharmaceutical technologies. With a focus on developing novel, cell-based allogeneic therapies using proprietary gamma delta T cell technology, CytoMed aims to offer new hope to patients suffering from various malignancies.
Frequently Asked Questions
What is the ANGELICA Trial?
The ANGELICA Trial is a Phase I clinical study focusing on using CAR-T cell therapy for treating blood and solid tumors.
What types of cells are used in CytoMed's trial?
The trial utilizes gamma delta T cells, sourced from healthy donors, allowing for a versatile application without the need for donor matching.
Who is leading the ANGELICA Trial?
Dr. Anand Jeyasekharan, a Senior Consultant at the National University Cancer Institute in Singapore, serves as the lead investigator.
What support has CytoMed received for this trial?
The trial has received co-funding from the National Medical Research Council under its Clinical Trial Grant scheme.
How does this trial differ from traditional CAR-T therapies?
This trial seeks to provide off-the-shelf CAR-T therapy using donor-derived gamma delta T cells, which operate with lower matching requirements and aim for quicker patient access.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Transform Your Grilling Experience with New Probes from recteq
- Emvolon Partners with Montauk to Innovate Carbon-Negative Fuels
- Exciting Growth for Chicken Salad Chick with New Location
- BeMe Health Enhances Gen Z Mental Health with Rock the Vote
- Carvana Expands Operations with New Megasite in Las Vegas
- VSS Capital Partners Strengthens Presence with Treya Investment
- Joining Forces: MAI Capital Management Expands with Halpern
- Ispire Technology Partners with ANDS to Enhance Global Presence
- City of Roseville Enhances Digital Payment Solutions with InvoiceCloud
- Sify Technologies Enhances Network Capacity with Ciena's Solutions
Recent Articles
- Exciting Launch of Charlotte’s Web CBD Gummies in Canada
- Microbix Unveils Innovative HSV Control Solution at EMMD
- Beasley Broadcast Group Completes Note Exchange Successfully
- AIRSUPRA® Significantly Lowers Severe Asthma Risks in Trials
- Exploring New Frontiers in Cancer Therapy with UNO
- Billionaires Target High-Growth FAANG Stocks for Success
- Marti Technologies Launches Ride-Hailing Monetization Strategy
- Unveiling the Potential of GT-02287 in Parkinson's Research
- Discover Top ETFs for Smart Investment Strategies
- Bruker Unveils OptoVolt for Enhanced Neuroscience Research
- InspireMD's Innovative CGuard Study Receives FDA Approval
- Cleveland-Cliffs Hosts Key Government Officials for Steel Industry
- Mural Oncology Showcases Innovations in Immuno-Oncology Research
- ViiV Healthcare Expands Access to Long-Acting HIV Prevention
- Foremost Clean Energy Partners with Denison Mines for Uranium Exploration
- Judo Bio Advances Gene Therapy Research for Kidney Treatment
- Chris Akrimi's New Role at NuORDER by Lightspeed Enhances Growth
- GXO Logistics Plans Earnings Call for Third Quarter 2024
- Oak Hill Bio Welcomes New Executive Leadership and Board Members
- Perspective Therapeutics Engages in Key Oncology Events Ahead
- Energy Recovery Announces Upcoming Financial Results and Webinar
- Generations Bancorp NY, Inc. Joins OTCQX for Enhanced Trading
- Consensus Cloud Solutions Plans Exciting Q3 Earnings Call
- Gray Media Expands Reach with New Local News Live Apps
- BPGbio Teams with Oxford University to Propel Protein Research Forward
- Rubicon Organics Unveils Comprehensive Sustainability Report
- Scholar Rock Celebrates Phase 3 Success for SMA Treatment
- NIU Technologies Unveils KQi 100F Electric Scooter at Expo
- Judo Bio Marks $100M Financing and Welcomes Rajiv Patni as CEO
- Virios and Wex Join Forces to Launch Dogwood Therapeutics
- Laser Photonics Expands to 50,000 sq. ft. Facility for Growth
- Blue Owl Capital's Strategic Move to Enhance Digital Infrastructure
- Chimney and Jack Henry Join Forces to Enhance Homeowner Engagement
- New Era of Flavor: Clark Foods Launches in the U.S. Market
- Leadership Expansion for Vantage Data Centers in APAC Region
- Welltower Sets Earnings Release Date for Q3 2024 Results
- Transforming Audits: The Role of AI and Human Expertise
- Situ Ve Promotes Respect and Empathy in Romantic Relationships
- Jetcraft Strengthens EMEA Sales Team with New Director Role
- Powerfleet Invites Investors to Day of Insights and Growth
- Kinaxis Strengthens Ono Pharmaceutical's Supply Chain Strategy
- Streamlining IT Procurement: SysAid Launches on AWS Marketplace
- Mason Capital Management Consortia's Strategic Acquisition of CB&I
- EVERSANA Strengthens Global Presence with New Office in Berlin
- Dundee Precious Metals Reports Robust Production Figures
- Capital Square Achieves Remarkable 136.42% Return on Investment
- Global Markets Update: Insights into Recent Trends and Movements
- Five Star Franchising Celebrates Success with Top Ten Ranking
- Veralto Strengthens Food Safety Solutions with TraceGains Purchase
- AerCap Achieves Major Milestones in Q3 with $10.5 Billion Financing